These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 24742492)
21. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163 [TBL] [Abstract][Full Text] [Related]
22. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Rivenbark AG; Livasy CA; Boyd CE; Keppler D; Coleman WB Exp Mol Pathol; 2007 Oct; 83(2):188-97. PubMed ID: 17540367 [TBL] [Abstract][Full Text] [Related]
23. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344 [TBL] [Abstract][Full Text] [Related]
24. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Song J; Jie C; Polk P; Shridhar R; Clair T; Zhang J; Yin L; Keppler D Biochem Biophys Res Commun; 2006 Feb; 340(1):175-82. PubMed ID: 16356477 [TBL] [Abstract][Full Text] [Related]
25. Legumain promotes fibrogenesis in chronic pancreatitis via activation of transforming growth factor β1. Ren YC; Zhao Q; He Y; Li B; Wu Z; Dai J; Wen L; Wang X; Hu G J Mol Med (Berl); 2020 Jun; 98(6):863-874. PubMed ID: 32415356 [TBL] [Abstract][Full Text] [Related]
26. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792 [TBL] [Abstract][Full Text] [Related]
27. Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M. Smith R; Johansen HT; Nilsen H; Haugen MH; Pettersen SJ; Mælandsmo GM; Abrahamson M; Solberg R Biochimie; 2012 Dec; 94(12):2590-9. PubMed ID: 22902879 [TBL] [Abstract][Full Text] [Related]
28. UV-mediated regulation of the anti-senescence factor Tbx2. Abrahams A; Mowla S; Parker MI; Goding CR; Prince S J Biol Chem; 2008 Jan; 283(4):2223-30. PubMed ID: 18025091 [TBL] [Abstract][Full Text] [Related]
29. Legumain affects the PI3K/AKT tumor progression pathway in retinoblastoma. Tang Q; Xu F; Lin J; Zhang C; Liu X; Dong L; Zhao J; Zhu L; Lin T Exp Eye Res; 2022 Nov; 224():109221. PubMed ID: 36041510 [TBL] [Abstract][Full Text] [Related]
30. MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression. Shi M; Yao Y; Han F; Li Y; Li Y PLoS One; 2014; 9(1):e86839. PubMed ID: 24466264 [TBL] [Abstract][Full Text] [Related]
31. HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression. Li Y; Chao F; Huang B; Liu D; Kim J; Huang S Oncotarget; 2014 May; 5(9):2596-607. PubMed ID: 24810778 [TBL] [Abstract][Full Text] [Related]
32. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257 [TBL] [Abstract][Full Text] [Related]
33. The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma. Liao K; Qian Z; Zhang S; Chen B; Li Z; Huang R; Cheng L; Wang T; Yang R; Lan J; Lu X; Kong L; Song X; Qiu Y; Lin Y Cancer Lett; 2020 Oct; 490():111-123. PubMed ID: 32711096 [TBL] [Abstract][Full Text] [Related]
34. Cystatin M/E knockdown by lentiviral delivery of shRNA impairs epidermal morphogenesis of human skin equivalents. Jansen PA; van den Bogaard EH; Kersten FF; Oostendorp C; van Vlijmen-Willems IM; Oji V; Traupe H; Hennies HC; Schalkwijk J; Zeeuwen PL Exp Dermatol; 2012 Nov; 21(11):889-91. PubMed ID: 23163660 [TBL] [Abstract][Full Text] [Related]
35. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription. Wen FC; Chang TW; Tseng YL; Lee JC; Chang MC Carcinogenesis; 2014 Jul; 35(7):1481-90. PubMed ID: 24403312 [TBL] [Abstract][Full Text] [Related]
36. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer. Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995 [TBL] [Abstract][Full Text] [Related]